@hadeanventures - Hadean Ventures

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on…

Transition into clinical-stage development marks a significant corporate and R&D milestone. Munich, Germany, October 17,…

Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion…

SciRhom GmbH is a German biotechnology company...

Attgeno AB today announces positive data from the company’s Phase IIa study, evaluating the effects…

Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian…

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease Bagsværd, Denmark, and…

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa...

Alex Therapeutics Reports Positive Results...

Hadean Ventures announces oversubscribed final close of Hadean Capital II